Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 21,500 | |||
5 mg | 在庫あり | ¥ 50,000 | |||
10 mg | 在庫あり | ¥ 74,000 | |||
25 mg | 在庫あり | ¥ 124,500 | |||
50 mg | 在庫あり | ¥ 179,000 | |||
100 mg | 在庫あり | ¥ 250,500 | |||
500 mg | 在庫あり | ¥ 500,500 |
説明 | Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR. |
ターゲット&IC50 | EGFR (L861Q):0.423 nM, EGFR (L858R):0.563 nM, EGFR (WT):0.611 nM, EGFR (T790M):45.2 nM |
In vivo | Larotinib (250, 300, 350 mg; oral; once daily; patients) demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety. A phase 3 study is underway on 350 mg larotinib in ESCC patients with EGFR overexpression.[1] |
分子量 | 488.94 |
分子式 | C24H26ClFN4O4 |
CAS No. | 1438072-11-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (122.71 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Larotinib 1438072-11-7 Angiogenesis Immunology/Inflammation JAK/STAT signaling NF-Κb Tyrosine Kinase/Adaptors EGFR BTK Tyrosine Kinases IRAK Inhibitor inhibitor inhibit